Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.53 USD | -3.95% | -3.61% | -20.85% |
05-20 | Insmed Lung Infections Treatment Study Shows Improvement | MT |
05-15 | Goldman Sachs Adjusts Price Target on Insmed to $49 From $40, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.85% | 3.8B | |
+8.63% | 115B | |
+13.17% | 107B | |
-12.76% | 22.31B | |
-3.99% | 21.6B | |
-7.19% | 18.23B | |
-39.93% | 17.62B | |
+6.67% | 14.26B | |
+33.90% | 12.37B | |
-28.60% | 8.28B |
- Stock Market
- Equities
- INSM Stock
- News Insmed Incorporated
- Cantor Fitzgerald Adjusts Price Target on Insmed to $46 From $49, Maintains Overweight Rating